39,663
Participants
Start Date
June 15, 2021
Primary Completion Date
January 31, 2022
Study Completion Date
November 1, 2023
Recombinant COVID-19 vaccine (Sf9 cells)
This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified by antigen isolation and added with aluminum hydroxide adjuvant for the prevention of COVID-19.
Placebo control
Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium dihydrogen phosphate, disodium hydrogen phosphate) are consistent with the study vaccine and have been tested and qualified by National Institutes for Food and Drug Control.
Quirino Memorial Medical Center, Quezon City
Tropical Disease Foundation, Makati City
Puskesmas Ciketingudik, Bekasi
Permata Hospital, Bekasi
Brawijaya University Hospital, Malang
Universitas Muhammadiyah Malang Hospital, Malang
Airlangga University Hospital, Surabaya
Husada Utama Hospital, Surabaya
Moi Teaching and Referral Hospital，Eldoret (MTRH), Eldoret
KAVI-Institute of Clinical Research, University of Nairobi, Nairobi
Instituto de Investigaciones Aplicadas a la Neurociencia A.C., Durango
Centro de Investigación Clínica y medicina traslacional (CIMeT), Guadalajara
Hospital General Dr. Manuel Gea González, Mexico City
Invesclinic MX, Mexico City
Clínica de Enfermedades Crónicas y de Procedimientos Especiales, Morelia
SMIQ，S de R.L. de C.V., Querétaro
FS Scientia Pharma SA de CV, San Luis Potosí City
Bharatpur Hospital, Kathmandu
Perpetual Succour Hospital - The Research Institute, Cebu City
St Luke Medical Centre - BGC, City of Taguig
De La Salle Medical and Health Sciences Institute, Dasmariñas
The Medical City - Iloilo, Iloilo City
West Visayas State University Medical Center, Iloilo City
Makati Medical Center, Makati City
West China Hospital
OTHER
WestVac Biopharma Co., Ltd.
INDUSTRY